Business
Curis Announces Date for the 2nd Annual VISTA Symposium
Industry experts in immuno-oncology will gather to discuss VISTA on September 23, 2022 Symposium hosted by Randolph Noelle, Ph.D. LEXINGTON, Mass., Sept. 19,
About this update from Curis, Inc.
[{"type":"text","content":"Industry experts in immuno-oncology will gather to discuss VISTA on September 23, 2022\nSymposium hosted by Randolph Noelle, Ph.D.\nLEXINGTON, Mass., Sept. 19, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the 2nd Annual VISTA Symposium will take place virtually on September 23, 9:00am-1:00pm ET.\n\n \n \n \n \n \n \n\n \nThe event will be hosted by Randolph Noelle, Ph.D., Active Emeritus Professor of Microbiology and Immunology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth. Global leaders in immuno-oncology will gather at the Symposium to discuss the VISTA checkpoint, its role in cancer, and the latest VISTA research and therapeutic development.\n\"Curis is pleased to continue its sponsorship of the Annual VISTA Symposium,\" said James Dentzer, President and Chief Executive Officer of Curis. \"As the global leader in VISTA development, we are honored to provide a forum for discussing the progress we're seeing with CI-8993, our own VISTA program, as well as programs from other companies and academic labs, as we collectively advance the forefront of VISTA research and development for the benefit of patients living with cancer.\"\nThe virtual event features agenda topics including:\nVISTA BiologyBiology OverviewVISTA ligands and counterreceptorsRole of VISTA in Tumor Immune EvasionVISTA TargetingThe PK/PD complexities of target mediated dispositionPET Imaging of VISTA targetingClinical Opportunities and QuestionsBiomarkers, pathways and tumor subsetsAnti-VISTA antibody in combination with radiation therapyTranslational immunology in cutaneous malignanciesAnti-VISTA Therapeutic StrategiesTo learn more about the symposium and register to attend, please visit https://bit.ly/VISTA22.\nAbout Curis, Inc.Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, emavusertib (CA-4948). E...